Boston Scientific (BSX) Change in Accured Expenses (2020 - 2026)

Boston Scientific has disclosed Change in Accured Expenses across 7 years of filings, most recently posting $234.0 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 1.3% year-over-year to $234.0 million; the TTM figure through Jun 2026 stood at $172.0 million (down 63.25% YoY), while the FY2025 annual figure was $296.0 million, up 21.81% from the prior year.
• Change in Accured Expenses came in at $234.0 million for Q2 2026 at Boston Scientific, up from -$512.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $385.0 million in Q4 2024 to a low of -$512.0 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $6.9 million, with a median of $47.0 million recorded in 2023.
• Year-over-year, Change in Accured Expenses sank 5357.14% in 2022 and jumped 1573.91% in 2024.
• Over 5 years, Change in Accured Expenses stood at $335.0 million in 2022, then sank by 93.13% to $23.0 million in 2023, then jumped by 1573.91% to $385.0 million in 2024, then retreated by 25.97% to $285.0 million in 2025, then slipped by 17.89% to $234.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $234.0 million in Q2 2026, -$512.0 million in Q1 2026, and $285.0 million in Q4 2025.